Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
Margolis, David A, Dr, Brinson, Cynthia C, MD, Smith, Graham H R, MD, de Vente, Jerome, MD, Hagins, Debbie P, MD, Eron, Joseph J, Prof, Griffith, Sandy K, PharmD, Clair, Marty H St, BS, Stevens, Marita C, MD, Williams, Peter E, PhD, Ford, Susan L, PharmD, Stancil, Britt S, BS, Bomar, Melinda M, BS, Hudson, Krischan J, PhD, Smith, Kimberly Y, MD, Spreen, William R, PharmD
Published in The Lancet infectious diseases (01.10.2015)
Published in The Lancet infectious diseases (01.10.2015)
Get full text
Journal Article